Guide to CJC-1295 DAC Peptide
CJC-1295 is a peptide developed to function similarly to GHRH, helping boost growth hormone levels. DAC is a biochemical complex that may significantly increase the life of the peptide within the body, so CJC-1295 with DAC may be a cost-effective option when deciding to get CJC 1295 with or without DAC. CJC-1295 & Ipamorelin blend has been studied for its apparently potent compounded effect, such as faster fat loss, increased muscle growth and repair, and even anti-aging properties. Before reviewing the CJC-1295 peptide, it is important to clarify what peptides are. In biology and science, peptides are compounds consisting of two or more amino acids connected through a peptide bond. Therefore, peptides are the building blocks of proteins. There are a huge number of different peptides, and depending on their amino acids, they have different roles in the body. Some play a role in skin care, others in muscle growth, etc. (1) The CJC-1295 peptide is a synthetic 29 amino acid analog of growth hormone-releasing hormone (GHRH). (2)
Growth Hormone-Releasing Hormone (GHRH) is primarily secreted by the hypothalamus, and stimulates Growth Hormone (GH) synthesis and secretion. The amount of GHRH produced depends on metabolic status, sex, and age. GHRH is closely related to sleep promotion and feeding regulation. In addition, the Growth Hormone that depends on GHRH has a metabolic role: it stimulates protein synthesis in the body, enhances the use of fat, and maintains blood glucose within a normal range. It also has a body growth role: it stimulates tissues, including the liver, to secrete growth factors that lead to bone growth. (4) Therefore, dysfunctions in GHRH can lead to abnormal growth.
CJC-1295 DAC Peptide Overview
CJC-1295 is known under many titles: CJC-1295, CJC-1295 with DAC, DAC:GRF, long-acting GHRH analog, and synthetic GHRH analog. Theoretically, as the peptide is considered a releasing factor for growth hormone, CJC-1295 has been studied for its potential role in:
- The reduction of fat mass by using the fat as an energy source. It may lead to an increased muscle mass via promoting the synthesis of proteins. These changes would lead to a better metabolic outcome and higher metabolic rate
- Since growth hormone promotes bone growth and improved joint and connective tissue health, CJC-1295 peptide may potentially improve bone mass and reduce injuries. Having better muscle and bone mass and avoiding injuries means that research subjects can have greater exercise performance and achieve better results.
- Studies have suggested that when GHRH is administered, it promotes sleep in humans. (5) Therefore, we suppose that the same or similar effect might occur after the administration of CJC-1295. This can potentially improve the sleep quality and increase the overall sense of well-being in subjects
There’s also increased levels of research being done with peptide blends, in particular CJC 1295 Ipamorelin Blend. To read more about this blend, read our CJC 1295 Ipamorelin Research Benefits blog post.
Research and Clinical Studies
CJC-1295 DAC Peptide Clinical Studies
In 2005, a study began to evaluate the efficacy, safety, and tolerability of CJC 1295 in patients with human immunodeficiency virus (HIV) associated with visceral obesity. In this study, the patients would be treated with CJC-1295 for 3 months and followed by a 6 week follow-up period. However, this study was terminated during the recruitment process, and no related results were posted. (6)
According to a Norwegian study, in 2009 an unknown pharmaceutical preparation was submitted for analysis to evaluate whether it contained prohibited substances or not. The researchers of the Norwegian Doping Control Laboratory and School of Pharmacy found out that this unknown substance was CJC-1295. In their published article they concluded that “CJC-1295 is a releasing factor for growth hormone” and that “it has potential performance-enhancing effects.” (2)
CJC-1295 DAC Peptide Safety and Efficacy Studies
Researchers conducted two studies in 2006 to examine the effects and safety of CJC-1295. The participants were healthy individuals between the ages of 21-61 years old. In the first study the CJC-1295 or placebo was administered in one of four ascending single doses. On the other side, in the second study CJC-1295 was administered in two or three weekly or biweekly doses. According to the results, after the administration of CJC-1295, there appeared to be a dose-dependent increase in GH and IGF-I levels (IGF-1: Insulin-like growth factor 1- is a hormone similar to insulin which plays a significant role during childhood on the growth, and has anabolic effects in adults) among the participants and no serious adverse effects were reported. (7)
In 2006, another group of scientists assessed the GH pulsatility after a single administration of CJC-1295. They found out that there appeared to be an increase of about 50% in GH secretion and IGF-I levels after the single dose of CJC-1295. Moreover, and in concordance with the previously mentioned study, none of the subjects appeared to experience any adverse effects. (8)
In addition to the human studies that took place, additional animal studies were conducted to evaluate the efficacy of CJC-1295. An interesting study was conducted using mice administered with the peptide or a placebo. The researchers concluded that once-daily doses of CJC-1295 might completely normalize growth. Another finding was that administration of CJC-1295 every 2 or 3 days produced intermediate results, indicating a probable interval-dependent effect. (9)
CJC-1295 DAC Peptide Half-life
In its original form, CJC-1295 uses a technology referred to as Drug Affinity Complex (DAC). However, most products currently sold as CJC‐1295, are non‐approved substances lacking the DAC feature. (2) Contrary to the GHRH which has a half-life of approximately 7 minutes, CJC-1295 appears to exhibit a longer half-life of 6-8 days due to the DAC technology. (10) There are few studies on its use and safety, therefore further research is needed to confirm the efficacy and safety of the CJC-1295 peptide, with or without DAC.
CJC-1295 DAC Safety Profile
As mentioned earlier in the analysis of related studies, there have been no serious adverse effects reported during the course of research studies. Of course, the administered dose, the duration, and the frequency are matters that play a crucial role when it comes to establishing side effects. Therefore, only when using the same doses, frequency, and duration of treatment can we be sure about its safety.
Specifically, in the study of Teichman and colleagues (2006) there were no reported significant increases in other hormones, including prolactin, LH levels, serum cortisol, or TSH, even after a single dose of CJC-1295, which appears to confirm the specificity of CJC-1295 for GH secretion. According to the researchers of the study, all the adverse effects were of mild to moderate severity that didn’t require any medical intervention to resolve. The most common adverse effects noticed were the administration site reactions including itching, pain, irritation, erythema, and induration that occurred transiently in 7 out of 10 of the subjects receiving CJC-1295 and rarely in the ones receiving placebo. It is worth mentioning that the irritation at administration were more severe and/or prolonged after higher doses. About a third of the participants experienced transient urticarial rashes at the site. Furthermore, actively treated subjects reported headache (in more than 60%), and diarrhea (in less than half of the subjects). Some other adverse effects reported were systemic vasodilatory reactions like flushing, transient hypotension but all were more common at higher doses. (7) According to a 2016 published article, the health risks of CJC-1295 include osteoporosis, cardiomyopathy, impotence, menstrual irregularities, potential blood-borne virus transmission in shared administration practices, and premature mortality from cardiovascular diseases. (10)
1. Linder J. The science behind peptides. Plast Surg Nurs. 2012 Apr-Jun;32(2):71-2. doi: 10.1097/PSN.0b013e3182577344. PMID: 22647954.
2. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2010 Nov-Dec;2(11-12):647-650. DOI: 10.1002/dta.233.
3. Kastin, A., 2006. Handbook of biologically active peptides. 1st ed. Amsterdam: Academic Press, CHAPTER 93 – Growth Hormone-Releasing Hormone pp.663-671.
4. Vivo.colostate.edu. 2021. Growth Hormone (Somatotropin). (online) Available at: (Accessed 26 April 2021).
5. Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep. 1997 Nov;20(11):1038-52. PMID: 9456470.
6. ClinicalTrials.gov, A service of the US National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/show/NCT00267527 (27 June 2010).
7. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.
8. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654.
9. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
10. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016 Jan 2;51(1):73-84. doi: 10.3109/10826084.2015.1082595. Epub 2016 Jan 15. PMID: 26771670.
11. World Anti-Doping Agency. 2021. What is Prohibited. (online) Available at: (Accessed 26 April 2021).
NOTE: These products are all intended for laboratory research use only. CJC 1295 with DAC for sale is not for personal use. Please review and adhere to our Terms and Conditions before ordering.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.